vs
Amplitude, Inc.（AMPL）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
VERACYTE, INC.的季度营收约是Amplitude, Inc.的1.5倍（$140.6M vs $91.4M），VERACYTE, INC.净利率更高（29.3% vs -19.3%，领先48.6%），VERACYTE, INC.同比增速更快（18.5% vs 17.0%），VERACYTE, INC.自由现金流更多（$48.8M vs $12.7M），过去两年VERACYTE, INC.的营收复合增速更高（20.5% vs 12.2%）
Amplitude是一家美国企业，专注于研发数字分析软件，能够帮助企业梳理用户行为数据、优化产品决策与数字化运营体验。该公司于2021年9月28日在纳斯达克交易所挂牌上市，股票代码为AMPL。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
AMPL vs VCYT — 直观对比
营收规模更大
VCYT
是对方的1.5倍
$91.4M
营收增速更快
VCYT
高出1.5%
17.0%
净利率更高
VCYT
高出48.6%
-19.3%
自由现金流更多
VCYT
多$36.2M
$12.7M
两年增速更快
VCYT
近两年复合增速
12.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $91.4M | $140.6M |
| 净利润 | $-17.7M | $41.1M |
| 毛利率 | 74.6% | 72.5% |
| 营业利润率 | -18.3% | 26.4% |
| 净利率 | -19.3% | 29.3% |
| 营收同比 | 17.0% | 18.5% |
| 净利润同比 | 45.8% | 704.8% |
| 每股收益（稀释后） | $-0.13 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPLVCYT
| Q4 25 | $91.4M | $140.6M | ||
| Q3 25 | $88.6M | $131.9M | ||
| Q2 25 | $83.3M | $130.2M | ||
| Q1 25 | $80.0M | $114.5M | ||
| Q4 24 | $78.1M | $118.6M | ||
| Q3 24 | $75.2M | $115.9M | ||
| Q2 24 | $73.3M | $114.4M | ||
| Q1 24 | $72.6M | $96.8M |
净利润AMPLVCYT
| Q4 25 | $-17.7M | $41.1M | ||
| Q3 25 | $-24.0M | $19.1M | ||
| Q2 25 | $-24.7M | $-980.0K | ||
| Q1 25 | $-22.2M | $7.0M | ||
| Q4 24 | $-32.6M | $5.1M | ||
| Q3 24 | $-16.9M | $15.2M | ||
| Q2 24 | $-23.4M | $5.7M | ||
| Q1 24 | $-21.5M | $-1.9M |
毛利率AMPLVCYT
| Q4 25 | 74.6% | 72.5% | ||
| Q3 25 | 73.9% | 69.2% | ||
| Q2 25 | 72.6% | 69.0% | ||
| Q1 25 | 74.7% | 69.5% | ||
| Q4 24 | 74.7% | 66.4% | ||
| Q3 24 | 75.1% | 68.2% | ||
| Q2 24 | 73.4% | 68.1% | ||
| Q1 24 | 74.0% | 64.5% |
营业利润率AMPLVCYT
| Q4 25 | -18.3% | 26.4% | ||
| Q3 25 | -26.0% | 17.4% | ||
| Q2 25 | -29.0% | -4.0% | ||
| Q1 25 | -26.8% | 2.5% | ||
| Q4 24 | -41.2% | 3.5% | ||
| Q3 24 | -21.4% | 10.4% | ||
| Q2 24 | -31.7% | 4.0% | ||
| Q1 24 | -29.0% | -4.8% |
净利率AMPLVCYT
| Q4 25 | -19.3% | 29.3% | ||
| Q3 25 | -27.1% | 14.5% | ||
| Q2 25 | -29.6% | -0.8% | ||
| Q1 25 | -27.8% | 6.2% | ||
| Q4 24 | -41.7% | 4.3% | ||
| Q3 24 | -22.4% | 13.1% | ||
| Q2 24 | -31.9% | 5.0% | ||
| Q1 24 | -29.5% | -1.9% |
每股收益（稀释后）AMPLVCYT
| Q4 25 | $-0.13 | $0.50 | ||
| Q3 25 | $-0.18 | $0.24 | ||
| Q2 25 | $-0.19 | $-0.01 | ||
| Q1 25 | $-0.17 | $0.09 | ||
| Q4 24 | $-0.25 | $0.07 | ||
| Q3 24 | $-0.14 | $0.19 | ||
| Q2 24 | $-0.19 | $0.07 | ||
| Q1 24 | $-0.18 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $192.0M | $362.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $245.3M | $1.3B |
| 总资产 | $420.7M | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMPLVCYT
| Q4 25 | $192.0M | $362.6M | ||
| Q3 25 | $189.2M | $315.6M | ||
| Q2 25 | $208.1M | $219.5M | ||
| Q1 25 | $209.0M | $186.1M | ||
| Q4 24 | $241.1M | $239.1M | ||
| Q3 24 | $319.9M | $274.1M | ||
| Q2 24 | $318.3M | $235.9M | ||
| Q1 24 | $316.1M | $209.2M |
股东权益AMPLVCYT
| Q4 25 | $245.3M | $1.3B | ||
| Q3 25 | $262.2M | $1.3B | ||
| Q2 25 | $279.5M | $1.2B | ||
| Q1 25 | $289.5M | $1.2B | ||
| Q4 24 | $296.6M | $1.2B | ||
| Q3 24 | $290.0M | $1.2B | ||
| Q2 24 | $287.3M | $1.1B | ||
| Q1 24 | $289.2M | $1.1B |
总资产AMPLVCYT
| Q4 25 | $420.7M | $1.4B | ||
| Q3 25 | $438.1M | $1.4B | ||
| Q2 25 | $456.6M | $1.3B | ||
| Q1 25 | $445.8M | $1.3B | ||
| Q4 24 | $445.9M | $1.3B | ||
| Q3 24 | $445.6M | $1.3B | ||
| Q2 24 | $445.4M | $1.2B | ||
| Q1 24 | $437.9M | $1.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $12.8M | $52.6M |
| 自由现金流经营现金流 - 资本支出 | $12.7M | $48.8M |
| 自由现金流率自由现金流/营收 | 13.8% | 34.7% |
| 资本支出强度资本支出/营收 | 0.2% | 2.7% |
| 现金转化率经营现金流/净利润 | — | 1.28× |
| 过去12个月自由现金流最近4个季度 | $28.2M | $126.6M |
8季度趋势，按日历期对齐
经营现金流AMPLVCYT
| Q4 25 | $12.8M | $52.6M | ||
| Q3 25 | $5.0M | $44.8M | ||
| Q2 25 | $20.1M | $33.6M | ||
| Q1 25 | $-8.0M | $5.4M | ||
| Q4 24 | $3.2M | $24.5M | ||
| Q3 24 | $6.2M | $30.0M | ||
| Q2 24 | $9.2M | $29.6M | ||
| Q1 24 | $-48.0K | $-9.0M |
自由现金流AMPLVCYT
| Q4 25 | $12.7M | $48.8M | ||
| Q3 25 | $4.5M | $42.0M | ||
| Q2 25 | $19.5M | $32.3M | ||
| Q1 25 | $-8.5M | $3.5M | ||
| Q4 24 | $2.4M | $20.4M | ||
| Q3 24 | $6.2M | $27.7M | ||
| Q2 24 | $8.6M | $26.8M | ||
| Q1 24 | $-405.0K | $-11.1M |
自由现金流率AMPLVCYT
| Q4 25 | 13.8% | 34.7% | ||
| Q3 25 | 5.1% | 31.8% | ||
| Q2 25 | 23.4% | 24.8% | ||
| Q1 25 | -10.6% | 3.1% | ||
| Q4 24 | 3.1% | 17.2% | ||
| Q3 24 | 8.2% | 23.9% | ||
| Q2 24 | 11.8% | 23.4% | ||
| Q1 24 | -0.6% | -11.5% |
资本支出强度AMPLVCYT
| Q4 25 | 0.2% | 2.7% | ||
| Q3 25 | 0.5% | 2.1% | ||
| Q2 25 | 0.6% | 1.0% | ||
| Q1 25 | 0.5% | 1.6% | ||
| Q4 24 | 1.0% | 3.5% | ||
| Q3 24 | 0.0% | 1.9% | ||
| Q2 24 | 0.8% | 2.4% | ||
| Q1 24 | 0.5% | 2.2% |
现金转化率AMPLVCYT
| Q4 25 | — | 1.28× | ||
| Q3 25 | — | 2.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.76× | ||
| Q4 24 | — | 4.80× | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 5.16× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPL
| US | $55.8M | 61% |
| International | $35.7M | 39% |
VCYT
| Testing | $135.8M | 97% |
| Products | $3.8M | 3% |
| Biopharmaceutical And Other | $686.0K | 0% |
